Wuhan Coronavirus Thread

[afako]

What a difference a year makes
View attachment 91326

This guy himself has funded Wuhan Lab and the coronavirus gain of research function. He knew about the activities going on there. When shit hit the fan, he tried to cover up by lapping up on China and went in bed with Democrats to attack Trump. Today he is feeling safe to reveal the truth. The US deep state is also involved and now it thinks the time to expose it on China's head.

 

[Mantospace]

Digvijay Singh reacts to Dipcovan, asks 'shouldn't DRDO concentrate on research related to Defence'


New Delhi: A day after the Defence Research and Development Organisation (DRDO) announced it had developed an antibody test kit for the early screening of COVID-19, Congress leader Digvijay Singh questioned if the agency under the Ministry of Defence (MoD) is into full-time research on health issues.

Digvijay Singh reacts to Dipcovan, asks 'shouldn't DRDO concentrate on research related to Defence'

Is Defence Research and Development Organisation into full-time research on health issues? Shouldn't they concentrate on research related to Defence: Congress leader Digvijay Singh

www.timesnownews.com

looks like the chinese paki stooges are hurt cuz nation is making progress in containing covid. Nation coming together for a single cause when needed is something these kind dont understand

i think he must know medicine also comes under defence category.

 

[ezsasa]

This guy himself has funded Wuhan Lab and the coronavirus gain of research function. He knew about the activities going on there. When shit hit the fan, he tried to cover up by lapping up on China and went in bed with Democrats to attack Trump. Today he is feeling safe to reveal the truth. The US deep state is also involved and now it thinks the time to expose it on China's head.

My take is that murican media & politicians will make some noise for a little bit, just so that people can't say they assisted the CCP cover up. nothing concrete is gonna come out of it.

 

[Lost user]

Covid vaccine India: Covishield output at 6 crore, Covaxin output at 2 crore doses/month; yet only 5 crore will be given by May-end | India News - Times of India

India News: The government in an affidavit in the Supreme Court earlier this month averred that Serum Institute of India (SII) was producing 6.5 crore doses of Co

m.timesofindia.com

The change in procurement.. with the states and private sector coming in the picture might have contributed to a temporary decline in vaccination.. This is also explained by the increase in the buffer stock with states by roughly 1 cr to 1.9 crore..That still leaves around 2 cr vaccines.. Where are they lying around.. in warehouses of SII and BB for lack of state deals ?

 

[Indrajit]

Never a good idea to use antibiotics, steroids or anti viral medications unless its a last resort. I think Indian medical system needs to regulate treatments covid or otherwise very carefully. Especially steroids are the worst

Wrong. Last resort is a guarantee to die. Anti virals have to be given as early as possible, otherwise pointless. Steroids are extremely useful for patients showing high inflammation symptoms but have a very small window when they can be effective. Antibiotics are prescribed to cover for any infections when steroids are used (because steroids are being used to suppress the immune response) or to cover up any other risk. Intemperate use of anything is bad but it’s important not to rubbish these medications because they are what is saving many lives in this epidemic.

 

[AMCA]

 

[Indrajit]

There is lots of noise going in western social media space regarding non approval of ivermectin by FDA and WHO for covid treatment . They are claiming its because its generic and cheap alternative ... whats india's policy regarding this does nyone knows ?? Is it replacement for remdevsir ?

Go by the Indian experience. There seems to be some claim on data(don’t know how conclusive)that it helps shorten the duration and reduces severity. It’s pretty much prescribed now to almost all who test positive. Not in severe cases though.

Remdesivir is another drug albeit more expensive but also controversial and similar doubts on its effectiveness.

 

[here2where]

Wuhan lab staff sought hospital care before COVID-19 outbreak disclosed, says media report

Wuhan lab staff sought hospital care before COVID-19 outbreak disclosed, says media report

The newspaper said the report may add weight to calls for a broader probe of whether the COVID-19 virus could have escaped from the laboratory.

www.thehindu.com

Wuhan lab staff sought hospital care before Covid-19 outbreak disclosed ..

Wuhan lab staff sought hospital care before Covid-19 outbreak disclosed: WSJ - Times of India

China News: Three researchers from China's Wuhan Institute of Virology (WIV) sought hospital care in November 2019, months before China disclosed the Covid-19 pan

timesofindia.indiatimes.com

man made disaster ...

 

[DownWithCCP]

Wuhan lab staff sought hospital care before COVID-19 outbreak disclosed, says media report

Wuhan lab staff sought hospital care before COVID-19 outbreak disclosed, says media report

The newspaper said the report may add weight to calls for a broader probe of whether the COVID-19 virus could have escaped from the laboratory.

www.thehindu.com

Wuhan lab staff sought hospital care before Covid-19 outbreak disclosed ..

Wuhan lab staff sought hospital care before Covid-19 outbreak disclosed: WSJ - Times of India

China News: Three researchers from China's Wuhan Institute of Virology (WIV) sought hospital care in November 2019, months before China disclosed the Covid-19 pan

timesofindia.indiatimes.com

man made disaster ...

Lmao I love how they cancelled Trump for telling the truth, called him all sorts of name only to realize he was right all along.

 

[doreamon]

Companies now producing minimum 8.5 crores per month in month of may .. But only 3.6 crores have been vaccinated by 22 may .

Covid vaccine India: Covishield output at 6 crore, Covaxin output at 2 crore doses/month; yet only 5 crore will be given by May-end | India News - Times of India

India News: The government in an affidavit in the Supreme Court earlier this month averred that Serum Institute of India (SII) was producing 6.5 crore doses of Co

m.timesofindia.com

 

[DownWithCCP]

Bruh these guys actually believed "bodies dying in streets", not saying people haven't died in appalling conditions but to actually believe every street in India is filled with dead/burning bodies is ridiculous.

 

[here2where]

Blr seems to have good supply of covishield .... lots of drives recently in nearby health centers and in corporates....

 

[Lost user]

Companies now producing minimum 8.5 crores per month in month of may .. But only 3.6 crores have been vaccinated by 22 may .

Covid vaccine India: Covishield output at 6 crore, Covaxin output at 2 crore doses/month; yet only 5 crore will be given by May-end | India News - Times of India

India News: The government in an affidavit in the Supreme Court earlier this month averred that Serum Institute of India (SII) was producing 6.5 crore doses of Co

m.timesofindia.com

So, GOI has told the Supreme Court on record that both companies together produce more than 8 crore doses.. So, either lots of vaccines are lying in warehouses waiting for state government/ private player orders,.. or is it that vaccines are still being exported ..

 

[here2where]

Troubling, considering we currently are ~17% 1 dose and ~3% both jabs.

Single dose only 33% effective against B.1.617.2 variant

Coronavirus | Single dose of vaccine half as effective as double dose against B.1.617.2 variant: U.K.

The finding is significant for India, relying heavily on Covishield, with B.1.617.2 becoming the dominant variant

www.thehindu.com

The finding is significant for India, relying heavily on Covishield, with B.1.617.2 becoming the dominant variant

A single dose of the AstraZeneca vaccine, in the United Kingdom, was only 33% effective in protecting against symptomatic COVID-19 coronavirus involving the B.1.617.2 variant, first identified in India, as compared to a 59% efficacy from two doses of the vaccine, a study by scientists at Public Health England (PHE) and multiple institutions in the United Kingdom has found.

The finding is significant for India, which is not only heavily reliant on Covishield — the AstraZeneca vaccine — or about 90% of vaccination but also because the scientists who analyse genome variants in India report that the B.1.617.2 variant is increasingly becoming the dominant variant in India. The variant has multiple mutations on the spike protein region, a portion on the coronavirus that helps it to infiltrate the human body. Laboratory studies in India testing the potency of Covishield and Covaxin have shown that fewer antibodies are produced against the B.1.617 variant (related to the 617.2) though the numbers are sizeable to trigger immunity. No similar studies, however have been publicly reported on the B.1.617.2 variant.

Anurag Agrawal, Director, Council of Scientific and Industrial Research (CSIR)-Institute of Genomics and Integrative Biology said that while the dominance of the 617.2 strain was concerning and required investigation to improve future versions of available vaccines, the study’s import for India was that all the groups at greatest risk — healthcare workers, frontline workers and those over 60 years — must be given two shots.

“The Centre’s current guidelines are to continue masking up even after getting vaccinated. These numbers from the PHE only reinforce that. The vaccines’ protection against severe disease continues to be fairly high and so after two doses to those most at risk, we should ensure a single dose for as many as possible,” he told The Hindu. India, while posting over 350,000 new cases a day battles a vaccine shortage with demand exceeding supply across age groups and some increase in supply expected only around August.


Reduced vaccine efficacy: Experts call for policy revisit

Reduced vaccine efficacy: Experts call for policy revisit

NEW DELHI: The latest study indicating that the existing Covid-19 vaccines may have reduced efficacy against the B.1.617 variant of SARS CoV-2 has prompted man

www.newindianexpress.com

The latest study indicating that the existing Covid-19 vaccines may have reduced efficacy against the B.1.617 variant of SARS CoV-2 has prompted many experts to urge the Centre to rethink its vaccination policy using fresh modelling and serosurveys. The B.1.617 variant of Covid- 19 is largely responsible for the ferocious second wave of the pandemic in India and has reached many countries, including the UK. The Indian government had recently decided to raise the gap between two doses of Covishield vaccine to 12-16 weeks from the earlier suggested interval of 6-8 weeks.

Though the government insisted that it was being done at the behest of technical input from the expert panel on vaccinations, many believe that this was mainly done due to the acute shortage of Covid-19 vaccines in India. The new data from the UK, as per a study carried out by Public Health England, suggests that the two doses of the AstraZeneca vaccine offer just 60% efficacy against the infection, while the protection after only one dose is much lower.

This vaccine, however, has 66% efficacy after both doses against the B.1.1.7 variant, first detected in the UK, and even higher efficacy against the variants which were circulating earlier. The same study showed that the Pfizer, also being used in the UK, was 88% effective against the B.1.617 variant, while its efficacy is over 93% against the B.1.1.7 variant. This concern that the available vaccines may not be working as effectively against the B.1.617 variant, first detected in India, had earlier led to lowering of the gap between two doses of AstraZeneca to 8 weeks, from the earlier interval of 12 weeks in the UK.

 

[here2where]

Booster and annual shots may be the new normal after all ....


Bharat Biotech's Third Dose Trial of Covid Vaccine to Start in AIIMS Patna and Delhi Today

Bharat Biotech's Third Dose Trial of Covid Vaccine to Start in AIIMS Patna and Delhi Today - News18

The booster dose is to be given six months after the participants had received their second dose in the trial, which had taken place between September and October 2020.

www.news18.com

 

[IndianYonko]

COVID-19 | Moderna declines Punjab's request for direct vaccine supply, says they 'deal only with Government of India'

Reeling under shortage of supply, the Punjab government has reached out to all top global vaccine makers, including Moderna, Johnson & Johnson, Pfizer-BioNTech and the producers of Russia's Sputnik V.

www.moneycontrol.com

Keju/Sisodia : pfizer
Amrinder : Moderna
.....
Lets see how list populates. Few best CMs are yet to show their intelligence.

 

[Deadtrap]

Troubling, considering we currently are ~17% 1 dose and ~3% both jabs.

Single dose only 33% effective against B.1.617.2 variant

Coronavirus | Single dose of vaccine half as effective as double dose against B.1.617.2 variant: U.K.

The finding is significant for India, relying heavily on Covishield, with B.1.617.2 becoming the dominant variant

www.thehindu.com

The finding is significant for India, relying heavily on Covishield, with B.1.617.2 becoming the dominant variant

A single dose of the AstraZeneca vaccine, in the United Kingdom, was only 33% effective in protecting against symptomatic COVID-19 coronavirus involving the B.1.617.2 variant, first identified in India, as compared to a 59% efficacy from two doses of the vaccine, a study by scientists at Public Health England (PHE) and multiple institutions in the United Kingdom has found.

The finding is significant for India, which is not only heavily reliant on Covishield — the AstraZeneca vaccine — or about 90% of vaccination but also because the scientists who analyse genome variants in India report that the B.1.617.2 variant is increasingly becoming the dominant variant in India. The variant has multiple mutations on the spike protein region, a portion on the coronavirus that helps it to infiltrate the human body. Laboratory studies in India testing the potency of Covishield and Covaxin have shown that fewer antibodies are produced against the B.1.617 variant (related to the 617.2) though the numbers are sizeable to trigger immunity. No similar studies, however have been publicly reported on the B.1.617.2 variant.

Anurag Agrawal, Director, Council of Scientific and Industrial Research (CSIR)-Institute of Genomics and Integrative Biology said that while the dominance of the 617.2 strain was concerning and required investigation to improve future versions of available vaccines, the study’s import for India was that all the groups at greatest risk — healthcare workers, frontline workers and those over 60 years — must be given two shots.

“The Centre’s current guidelines are to continue masking up even after getting vaccinated. These numbers from the PHE only reinforce that. The vaccines’ protection against severe disease continues to be fairly high and so after two doses to those most at risk, we should ensure a single dose for as many as possible,” he told The Hindu. India, while posting over 350,000 new cases a day battles a vaccine shortage with demand exceeding supply across age groups and some increase in supply expected only around August.


Reduced vaccine efficacy: Experts call for policy revisit

Reduced vaccine efficacy: Experts call for policy revisit

NEW DELHI: The latest study indicating that the existing Covid-19 vaccines may have reduced efficacy against the B.1.617 variant of SARS CoV-2 has prompted man

www.newindianexpress.com

The latest study indicating that the existing Covid-19 vaccines may have reduced efficacy against the B.1.617 variant of SARS CoV-2 has prompted many experts to urge the Centre to rethink its vaccination policy using fresh modelling and serosurveys. The B.1.617 variant of Covid- 19 is largely responsible for the ferocious second wave of the pandemic in India and has reached many countries, including the UK. The Indian government had recently decided to raise the gap between two doses of Covishield vaccine to 12-16 weeks from the earlier suggested interval of 6-8 weeks.

Though the government insisted that it was being done at the behest of technical input from the expert panel on vaccinations, many believe that this was mainly done due to the acute shortage of Covid-19 vaccines in India. The new data from the UK, as per a study carried out by Public Health England, suggests that the two doses of the AstraZeneca vaccine offer just 60% efficacy against the infection, while the protection after only one dose is much lower.

This vaccine, however, has 66% efficacy after both doses against the B.1.1.7 variant, first detected in the UK, and even higher efficacy against the variants which were circulating earlier. The same study showed that the Pfizer, also being used in the UK, was 88% effective against the B.1.617 variant, while its efficacy is over 93% against the B.1.1.7 variant. This concern that the available vaccines may not be working as effectively against the B.1.617 variant, first detected in India, had earlier led to lowering of the gap between two doses of AstraZeneca to 8 weeks, from the earlier interval of 12 weeks in the UK.

Fuck bc they are already making us wait 12 weeks

 

[Jimih]

 

[omaebakabaka]

Wrong. Last resort is a guarantee to die. Anti virals have to be given as early as possible, otherwise pointless. Steroids are extremely useful for patients showing high inflammation symptoms but have a very small window when they can be effective. Antibiotics are prescribed to cover for any infections when steroids are used (because steroids are being used to suppress the immune response) or to cover up any other risk. Intemperate use of anything is bad but it’s important not to rubbish these medications because they are what is saving many lives in this epidemic.

Hmm, I should have qualified it as personal opinion as I am not a medical professional. People need to live a preventive life style vs getting on to meds as first step and doctors should recommend it. They said the same thing about pain killers and opiods is an epidemic in the west now....what idiotic govt advertizes drugs on tv? Insurance and medical professionals with big hospitals work hand in hand with focus on bottom line and with legal system sword on their head, they are too eager to prescribe all sorts of medication. Ofcourse covid is a special case, I was mostly talking in normal times.

 

[sorcerer]

India crosses a major landmark with more than 1 Cr vaccine doses administered for 18-44 age group under Phase-3 of Vaccination Drive




India has crossed a significant landmark in its fight against COVID19 pandemic today. The country has administered more than 1 Cr (1,06,21,235) Vaccine Doses for 18-44 age group under Phase-3 of Vaccination Drive. Vaccination is an integral pillar of the comprehensive strategy of Government of India for containment and management of the pandemic, along with Test, Track, Treat and COVID Appropriate Behaviour. Implementation of the Liberalized and Accelerated Phase-3 Strategy of Covid-19 Vaccination has started from 1st May 2021.

S. No.	States	Total
1	A & N Islands	4,082
2	Andhra Pradesh	8,891
3	Arunachal Pradesh	17,777
4	Assam	4,33,615
5	Bihar	12,27,279
6	Chandigarh	18,613
7	Chhattisgarh	7,01,945
8	Dadra & Nagar Haveli	18,269
9	Daman & Diu	19,802
10	Delhi	9,15,275
11	Goa	30,983
12	Gujarat	6,89,234
13	Haryana	7,20,681
14	Himachal Pradesh	40,272
15	Jammu & Kashmir	37,562
16	Jharkhand	3,69,847
17	Karnataka	1,97,693
18	Kerala	30,555
19	Ladakh	3,845
20	Lakshadweep	1,770
21	Madhya Pradesh	7,72,873
22	Maharashtra	7,06,853
23	Manipur	9,110
24	Meghalaya	23,142
25	Mizoram	10,676
26	Nagaland	7,376
27	Odisha	3,06,167
28	Puducherry	5,411
29	Punjab	3,70,413
30	Rajasthan	13,17,060
31	Sikkim	6,712
32	Tamil Nadu	53,216
33	Telangana	654
34	Tripura	53,957
35	Uttar Pradesh	10,70,642
36	Uttarakhand	2,20,249
37	West Bengal	1,98,734
Total	1,06,21,235

The cumulative number of COVID-19 vaccine doses administered in the country exceeded 19.60 Cr today under the Phase-3 of the nationwide Vaccination Drive.





A total of 19,60,51,962 vaccine doses have been administered through 28,16,725 sessions, as per the provisional report till 7 am today. These include 97,60,444 HCWs who have taken the 1st dose and 67,06,890 HCWs who have taken the 2nddose, 1,49,91,357 FLWs (1stdose), 83,33,774 FLWs (2nddose), 1,06,21,235 beneficiaries under 18-44 age group (1stdose), 6,09,11,756 (1stdose) and 98,18,384 (2nd dose) beneficiaries aged 45 to 60 years. 5,66,45,457 1stdose beneficiaries and 1,82,62,665 2nd dose beneficiaries of more than 60 years old.

HCWs	1st Dose	97,60,444
2nd Dose	67,06,890
FLWs	1st Dose	1,49,91,357
2nd Dose	83,33,774
Age Group 18-44 years	1st Dose	1,06,21,235
Age Group 45 to 60 years	1st Dose	6,09,11,756
2nd Dose	98,18,384
Over 60 years	1st Dose	5,66,45,457
2nd Dose	1,82,62,665
Total	19,60,51,962

Ten states account for 66.30% of the total doses given so far in the country.

India’s Daily Recoveries continue to outnumber the Daily New Cases for the 11th consecutive day. 3,02,544 recoveries were registered in the last 24 hours.


India’s cumulative recoveries have reached 2,37,28,011 today. The National Recovery Rate has grown further to touch 88.69%.


Ten states account for 72.23% of the new recoveries.

In another positive development, India has recorded less than 3 lakh Daily New Cases for eight consecutive days now. The gap between Daily New Cases and Daily Recovered Cases has reduced to 80,229 today.


India’s Daily New cases and recovered cases trajectory is shown below.

2,22,315 Daily New Cases were registered in the last 24 hours.


Ten States reported 81.08% of the new cases in last 24 hours. Tamil Nadu has reported the highest daily new cases at 35,483, followed by Maharashtra with 26,672 new cases.

India’s active caseload trajectory is shown below. Active Cases have decreased since its last peak on 10th May 2021.

India’s total Active Caseload has decreased to 27,20,716 today.


A net decline of 84,683 is witnessed in the last 24 hours. It now comprises 10.17% of the country's total Positive Cases.


8 States cumulatively account for 71.62% of India’s total Active Cases.

A total of 19,28,127 tests were conducted in the last 24 hours in the country and cumulatively 33,05,36,064 tests have been done so far. The Cumulative Positivity rate stands at 8.09% today. Weekly Positivity Rate has also declined to 12.66%.

The National Mortality Rate currently stands at 1.14%.


4,454 deaths were reported in the last 24 hours.


Ten States account for 79.52% of the new deaths in the last 24 hours. Maharashtra saw the maximum casualties (1,320). Karnataka follows with 624 daily deaths.

18 states/UTs have a Case Fatality Rate less than the national average (1.14%)

18 states/UTs have a Case Fatality Rate more than the national average.

****


MV